The Latest Breaking News from Biogen

As biotech stocks swing back into favor on Wall Street, here's a look at five picks that could deliver significant gains, according to analysts.

Despite macroeconomic challenges, the biotech industry thrives on innovation, demand, adaptability, and technological advancements, demonstrating resilience. So, let’s analyze the upside potential of popular biotech stocks Biogen (BIIB) and Moderna (MRNA).

Biogen's turnaround is still a "work in progress," an analyst said Tuesday as Biogen stock slumped on light fourth-quarter profit.

Because of its strategic focus on research and therapy improvements for long-term growth, Biogen (BIIB) could come under heat for the mixed outcomes of its recent acquisitions. As stakeholders anticipate the forthcoming earnings release, let's seek insights into the company's future trajectory and implications for BIIB shares. Read on….

A controversial Alzheimer's drug that was trumpeted as the first to ever treat the cognitive decline associated with the devastating brain disorder has been pulled from the market, its maker Biogen announced Wednesday.

Biotech stocks are heating up as multibillion-dollar deals pile up and new modalities like CRISPR gene-editing hit prime time.

Drug patent monopolies cost each family $5,000 per year

Biogen and Eisai scored key victories in the quest for an Alzheimer's cure. But the race is just getting started.

The stock market rally erased weekly gains as the major indexes ended long win streaks amid rebounding yields. Datadog led earnings winners.

Biogen stock skidded Wednesday on a "low-quality" sales beat that relied on other revenue. But analysts noted Skyclarys' strong launch.

Biotech major Biogen (BIIB) will report its third-quarter results on November 8. Its EPS and revenue are expected to decline year-over-year. However, the FDA approvals for new drugs received by the company this year will likely support its long-term growth. Let’s discuss the potential road ahead for the stock….